Deciphering the STAT3-PXN positive feedback loop in GBM, IDH-wildtype: transcriptional regulation and inhibition of YB-1 ubiquitination

Pouyan A, Ghorbanlo M, Eslami M, Jahanshahi M, Ziaei E, Salami A, et al. Glioblastoma multiforme: insights into pathogenesis, key signaling pathways, and therapeutic strategies. Mol Cancer. 2025;24:58. https://doi.org/10.1186/s12943-025-02267-0.

Google Scholar 

Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, et al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–51. https://doi.org/10.1093/neuonc/noab106.

Google Scholar 

Singh S, Dey D, Barik D, Mohapatra I, Kim S, Sharma M, et al. Glioblastoma at the crossroads: current understanding and future therapeutic horizons. Signal Transduct Target Ther. 2025;10:213 https://doi.org/10.1038/s41392-025-02299-4.

Google Scholar 

Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: a review. Jama. 2023;329:574–87. https://doi.org/10.1001/jama.2023.0023.

Google Scholar 

Mishchenko TA, Olajide OJ, Gorshkova EN, Vedunova MV, Krysko DV. Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy. Trends Cancer. 2025;11:430–2. https://doi.org/10.1016/j.trecan.2025.01.007.

Google Scholar 

Athanassiou H, Synodinou M, Maragoudakis E, Paraskevaidis M, Verigos C, Misailidou D, et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J Clin Oncol. 2005;23:2372–7. https://doi.org/10.1200/jco.2005.00.331.

Google Scholar 

Chen X, Zhang M, Gan H, Wang H, Lee JH, Fang D, et al. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma. Nat Commun. 2018;9:2949. https://doi.org/10.1038/s41467-018-05373-4.

Google Scholar 

Mishra YG, Manavathi B. Focal adhesion dynamics in cellular function and disease. Cell Signal. 2021;85:110046. https://doi.org/10.1016/j.cellsig.2021.110046.

Google Scholar 

Brown MC, Turner CE. Paxillin: adapting to change. Physiol Rev. 2004;84:1315–39. https://doi.org/10.1152/physrev.00002.2004.

Google Scholar 

Turner CE. Paxillin and focal adhesion signalling. Nat Cell Biol. 2000;2:E231–6. https://doi.org/10.1038/35046659.

Google Scholar 

López-Colomé AM, Lee-Rivera I, Benavides-Hidalgo R, López E. Paxillin: a crossroad in pathological cell migration. J Hematol Oncol. 2017;10:50 https://doi.org/10.1186/s13045-017-0418-y.

Google Scholar 

Sen A, De Castro I, Defranco DB, Deng FM, Melamed J, Kapur P, et al. Paxillin mediates extranuclear and intranuclear signaling in prostate cancer proliferation. J Clin Invest. 2012;122:2469–81. https://doi.org/10.1172/jci62044.

Google Scholar 

Chen DL, Wang DS, Wu WJ, Zeng ZL, Luo HY, Qiu MZ, et al. Overexpression of paxillin induced by miR-137 suppression promotes tumor progression and metastasis in colorectal cancer. Carcinogenesis. 2013;34:803–11. https://doi.org/10.1093/carcin/bgs400.

Google Scholar 

Wu DW, Cheng YW, Wang J, Chen CY, Lee H. Paxillin predicts survival and relapse in non-small cell lung cancer by microRNA-218 targeting. Cancer Res. 2010;70:10392–401. https://doi.org/10.1158/0008-5472.Can-10-2341.

Google Scholar 

Meng LQ, Zhang LY, Xu WZ. Paxillin is a potential prognostic biomarker associated with immune cell infiltration in ovarian cancer. Heliyon. 2023;9:e14095. https://doi.org/10.1016/j.heliyon.2023.e14095.

Google Scholar 

Wu DW, Chuang CY, Lin WL, Sung WW, Cheng YW, Lee H. Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting. Carcinogenesis. 2014;35:1823–9. https://doi.org/10.1093/carcin/bgu102.

Google Scholar 

Wu DW, Wu TC, Wu JY, Cheng YW, Chen YC, Lee MC, et al. Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression. Oncogene. 2014;33:4385–95. https://doi.org/10.1038/onc.2013.389.

Google Scholar 

de Semir D, Bezrookove V, Nosrati M, Scanlon KR, Singer E, Judkins J, et al. PHIP drives glioblastoma motility and invasion by regulating the focal adhesion complex. Proc Natl Acad Sci USA. 2020;117:9064–73. https://doi.org/10.1073/pnas.1914505117.

Google Scholar 

Huang H, Zhang W, Wu Q, Zhang L, Wu Y, Tong H, et al. Fucoxanthin targets β1 integrin to disrupt adhesion and migration in human glioma cells. J Agric Food Chem. 2025;73:10961–73. https://doi.org/10.1021/acs.jafc.4c10108.

Google Scholar 

Zepecki JP, Snyder KM, Moreno MM, Fajardo E, Fiser A, Ness J, et al. Regulation of human glioma cell migration, tumor growth, and stemness gene expression using a Lck targeted inhibitor. Oncogene. 2019;38:1734–50. https://doi.org/10.1038/s41388-018-0546-z.

Google Scholar 

Piao Y, Lu L, de Groot J. AMPA receptors promote perivascular glioma invasion via beta1 integrin-dependent adhesion to the extracellular matrix. Neuro Oncol. 2009;11:260–73. https://doi.org/10.1215/15228517-2008-094.

Google Scholar 

Lange K, Kammerer M, Saupe F, Hegi ME, Grotegut S, Fluri E, et al. Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res. 2008;68:6942–52. https://doi.org/10.1158/0008-5472.Can-08-0347.

Google Scholar 

Sloan KE, Stewart JK, Treloar AF, Matthews RT, Jay DG. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res. 2005;65:10930–7. https://doi.org/10.1158/0008-5472.Can-05-1890.

Google Scholar 

Sun LH, Yang FQ, Zhang CB, Wu YP, Liang JS, Jin S, et al. Overexpression of paxillin correlates with tumor progression and predicts poor survival in glioblastoma. CNS Neurosci Ther. 2017;23:69–75. https://doi.org/10.1111/cns.12606.

Google Scholar 

Chen B, Xia L, Xu CS, Xiao F, Wang YF. Paxillin functions as an oncogene in human gliomas by promoting cell migration and invasion. Onco Targets Ther. 2016;9:6935–43. https://doi.org/10.2147/ott.S114229.

Google Scholar 

Noh K, Bach DH, Choi HJ, Kim MS, Wu SY, Pradeep S, et al. The hidden role of paxillin: localization to nucleus promotes tumor angiogenesis. Oncogene. 2021;40:384–95. https://doi.org/10.1038/s41388-020-01517-3.

Google Scholar 

Yin, Q, Zheng, M, Luo, Q, Jiang, D, Zhang, H & Chen, C YB-1 as an oncoprotein: functions, regulation, post-translational modifications, and targeted therapy. Cells 11 https://doi.org/10.3390/cells11071217 (2022).

Park J, Cho J, Song EJ. Ubiquitin-proteasome system (UPS) as a target for anticancer treatment. Arch Pharm Res. 2020;43:1144–61. https://doi.org/10.1007/s12272-020-01281-8.

Google Scholar 

Gao Y, Fotovati A, Lee C, Wang M, Cote G, Guns E, et al. Inhibition of Y-box binding protein-1 slows the growth of glioblastoma multiforme and sensitizes to temozolomide independent O6-methylguanine-DNA methyltransferase. Mol Cancer Therapeutics. 2009;8:3276–84. https://doi.org/10.1158/1535-7163.Mct-09-0478.

Google Scholar 

Wang JZ, Zhu H, You P, Liu H, Wang WK, Fan X, et al. Upregulated YB-1 protein promotes glioblastoma growth through a YB-1/CCT4/mLST8/mTOR pathway. The Journal of clinical investigation 2022;132. https://doi.org/10.1172/jci146536.

Xu Y, Stamenkovic I, Yu Q. CD44 attenuates activation of the hippo signaling pathway and is a prime therapeutic target for glioblastoma. Cancer Res. 2010;70:2455–64. https://doi.org/10.1158/0008-5472.Can-09-2505.

Google Scholar 

Kumari S, Gupta R, Ambasta RK, Kumar P. Multiple therapeutic approaches of glioblastoma multiforme: from terminal to therapy. Biochim Biophys Acta Rev Cancer. 2023;1878:188913. https://doi.org/10.1016/j.bbcan.2023.188913.

Google Scholar 

Lindemann C, Hackmann O, Delic S, Schmidt N, Reifenberger G, Riemenschneider MJ. SOCS3 promoter methylation is mutually exclusive to EGFR amplification in gliomas and promotes glioma cell invasion through STAT3 and FAK activation. Acta Neuropathologica. 2011;122:241–51. https://doi.org/10.1007/s00401-011-0832-0.

Google Scholar 

Hu Y, Dong Z, Liu K. Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery. J Exp Clin Cancer Res. 2024;43:23 https://doi.org/10.1186/s13046-024-02949-5.

Google Scholar 

Caner A, Asik E, Ozpolat B. SRC signaling in cancer and tumor microenvironment. Adv Exp Med Biol. 2021;1270:57–71. https://doi.org/10.1007/978-3-030-47189-7_4.

Google Scholar 

Parsons SJ, Parsons JT. SRC family kinases, key regulators of signal transduction. Oncogene. 2004;23:7906–9. https://doi.org/10.1038/sj.onc.1208160.

Google Scholar 

Du X, Tu Y, Liu S, Zhao P, Bao Z, Li C, et al. LINC00511 contributes to glioblastoma tumorigenesis and epithelial-mesenchymal transition via LINC00511/miR-524-5p/YB1/ZEB1 positive feedback loop. J Cell Mol Med. 2020;24:1474–87. https://doi.org/10.1111/jcmm.14829.

Google Scholar 

Wang W, Hu D, Feng Y, Wu C, Song Y, Liu W, et al. Paxillin mediates ATP-induced activation of P2X7 receptor and NLRP3 inflammasome. BMC Biol. 2020;18:182. https://doi.org/10.1186/s12915-020-00918-w.

Google Scholar 

Tong H, Zhao K, Zhang J, Zhu J, Xiao J. YB-1 modulates the drug resistance of glioma cells by activation of MDM2/p53 pathway. Drug Des Devel Ther. 2019;13:317–26. https://doi.org/10.2147/dddt.S185514.

Google Scholar 

Min HY, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54:1670–94. https://doi.org/10.1038/s12276-022-00864-3.

Google Scholar 

Zhong L, Li Y, Xiong L, Wang W, Wu M, Yuan T, et al. Small molecules in targeted cancer therapy: advances, challenges, and future perspectives. Signal Transduct Target Ther. 2021;6:201 https://doi.org/10.1038/s41392-021-00572-w.

Google Scholar 

Noorani I, de la Rosa J. Breaking barriers for glioblastoma with a path to enhanced drug delivery. Nat Commun. 2023;14:5909. https://doi.org/10.1038/s41467-023-41694-9.

Google Scholar 

Luo Y, Yang H, Zhou YF, Hu B. Dual and multi-targeted nanoparticles for site-specific brain drug delivery. J Control Release Official J Controlled Release Soc. 2020;317:195–215. https://doi.org/10.1016/j.jconrel.2019.11.037.

Google Scholar